Pestalozzi advises 3i and ten23 health in the acquisition of swissfillon AG

Ten23 health, a pure-play, patient-centric and sustainable biologics drug product contract development and manufacturing organisation (“CDMO”), backed by 3i Group plc., acquired all shares in swissfillon AG, an FDA and Swissmedic approved drug product-focused CDMO active in the sterile filling of complex pharmaceuticals into innovative containers and devices, such as pre-filled syringes, cartridges and vials.

Pestalozzi advised 3i Group plc and its subsidiary ten23 health on all Swiss law aspects of the transaction.

The Pestalozzi team included:
Beat Schwarz (Partner - Corporate / M&A), Martin L. Mueller (Partner - Employment & Pensions), Nils Harbeke (Partner - Tax), Sarah Drukarch (Senior Associate - Life Sciences), Raphael Widmer (Associate - Corporate / M&A), Andrea P. Rohrer-Lippuner (Senior Associate - Real Estate & Environment), Florian Schnyder (Associate - Corporate / M&A), Larissa Rickenbacher (Associate - Real Estate & Environment), Hannes F. Baumgartner (Associate - Corporate / M&A), Martina Herzog (Associate - Employment), Odette Geldof (Junior Associate - Corporate / M&A)

Pestalozzi Attorneys at Law Ltd.
Zurich – Feldeggstrasse 4 | 8008 Zurich | Switzerland | T +41 44 217 91 11
Geneva – Cours de Rive 13 | 1204 Geneva | Switzerland | T +41 22 999 96 00
www.pestalozzilaw.com